CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics has moved to commercialization with its first approved CRISPR gene therapy, but fiscal 2025 revenue was only ~$3.5M (down ~90%) alongside a ~$581.6M net loss and negative free cash flow of ~$345.9M. Viking Therapeutics remains pre-revenue (no 2025 revenue), with a ~$359.6M net loss and negative free cash flow of ~$278.7M, dependent on its Ligand licensing deal and third-party manufacturing. The piece frames both as highly speculative while noting CRISPR is relatively more investible due to having commercialization, despite steep valuation (e.g., forward P/E ~19.1 vs VKTX ~17.7).

Analysis

The market is likely over-assigning value to the label "commercial stage" for CRSP. In gene-editing, the first dollars are rarely the hard part; durable monetization depends on referral flows, payer friction, and whether one partner can scale a niche therapy without the parent company owning the operating leverage. That makes the cash burn vs. revenue gap the real issue, not the headline approval. VRTX is the cleaner economic winner because it captures the operating upside of launch while CRSP still carries the scientific, legal, and balance-sheet burden.

VKTX is the opposite setup: more upside convexity, but the market is already paying for a best-case obesity outcome before the company has proven manufacturing, tolerability, or commercial differentiation. In a crowded GLP-1 landscape, late entrants need either meaningfully better efficacy or a cleaner side-effect profile; otherwise they become acquisition targets or dilution stories rather than platform winners. Third-party CMO dependence also turns what looks like a clinical story into a supply-chain execution trade.

Time horizon matters: over days, this article is mostly noise; over 1-3 months, the catalysts are data updates, legal milestones, and any signs that CRSP’s launch can scale beyond a science project. Over 6-18 months, the likely bifurcation is between VRTX as a profitable cash compounder and the rest of the gene-editing/obesity basket as multiple compression candidates if commercialization lags. The contrarian view is that the crowd is probably underestimating how slow rare-disease adoption can be and overestimating how easily obesity entrants can displace incumbents.

Key Decisions for Investors

• Long VRTX / short CRSP as a 3-6 month relative-value pair: own the monetization engine rather than the science platform; thesis breaks if CRSP shows a clear revenue inflection or VRTX launch economics disappoint.
• Avoid outright long VKTX ahead of de-risking; if you want upside optionality, use a small, defined-risk call spread only after a catalyst or manufacturing update confirms execution.
• Use XBI as the cleaner sector hedge if biotech sentiment improves broadly: short VKTX against XBI on strength to express the view that pre-revenue obesity names should underperform once the easy narrative premium fades.
• Set an alert on CRSP for two consecutive quarters of launch traction versus burn: if collaboration/launch revenue does not visibly narrow the cash-burn gap, the "commercial-stage" premium should compress further.